Overview

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Status:
Completed

Trial end date:
2016-04-22

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the antiviral efficacy of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) therapy at the time of liver transplantation and through 4 weeks posttransplant in adults with genotype 1 or 4 hepatitis C virus (HCV) infection who are undergoing primary liver transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ledipasvir
Ledipasvir, sofosbuvir drug combination
Sofosbuvir